Affimed Operating Income 2014-2024 | AFMDQ
Affimed operating income from 2014 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Affimed Annual Operating Income
(Millions of US $) |
| 2023 |
$-115 |
| 2022 |
$-93 |
| 2021 |
$-76 |
| 2020 |
$-40 |
| 2019 |
$-36 |
| 2018 |
$-23 |
| 2017 |
$-31 |
| 2016 |
$-35 |
| 2015 |
$-24 |
| 2014 |
$-11 |
| 2013 |
$7 |
| 2012 |
$2 |
Affimed Quarterly Operating Income
(Millions of US $) |
| 2024-09-30 |
$-16 |
| 2024-06-30 |
$-17 |
| 2024-03-31 |
$-21 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-27 |
| 2023-06-30 |
$-32 |
| 2023-03-31 |
$-34 |
| 2022-12-31 |
$-31 |
| 2022-09-30 |
$-19 |
| 2022-06-30 |
$-23 |
| 2022-03-31 |
$-19 |
| 2021-12-31 |
$-28 |
| 2021-09-30 |
$-22 |
| 2021-06-30 |
$-21 |
| 2021-03-31 |
$-5 |
| 2020-12-31 |
$-13 |
| 2020-09-30 |
$-3 |
| 2020-06-30 |
$-12 |
| 2020-03-31 |
$-11 |
| 2019-12-31 |
$-13 |
| 2019-09-30 |
$-14 |
| 2019-06-30 |
$-11 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$12 |
| 2018-09-30 |
$-14 |
| 2018-06-30 |
$-11 |
| 2018-03-31 |
$-10 |
| 2017-12-31 |
$-7 |
| 2017-09-30 |
$-9 |
| 2017-06-30 |
$-7 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-7 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-10 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-8 |
| 2015-09-30 |
$-8 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-3 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$1 |
| 2013-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
